...
首页> 外文期刊>Cancer Management and Research >PRISMA –?Practical meta-analysis of applying local triamcinolone acetonide injection for stenosis after esophageal cancer surgery
【24h】

PRISMA –?Practical meta-analysis of applying local triamcinolone acetonide injection for stenosis after esophageal cancer surgery

机译:PRISMA –食管癌手术后局部应用曲安奈德注射液治疗狭窄的实用荟萃分析

获取原文
           

摘要

Objectives: To explore the practical method of endoscopic triamcinolone acetonide (TA) injection immediately after endoscopic surgery and combined with endoscopic dilation (ED) in the management of stenosis after esophageal cancer surgery based on their efficacy and safety. Methods: A comprehensive search was performed in electronic databases including MEDLINE, EMBASE, the Cochrane Library, Web of Science, and China National Knowledge Infrastructure for possible controlled studies. Meta-analyses of the included studies were completed using Reviewer Manager software and were reported based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Results: Eight randomized studies and five controlled studies containing 575 patients were obtained. In five studies (n=282), TA injected after surgery reduced the risk of stenosis (risk difference [RD] =–0.51, 95%?CI?[–0.64,?–0.39], P 0.01) and the required ED sessions (RD =–3.66, 95%?CI?[–5.87,?–1.46], P 0.01). In eight studies (n=293), TA injection combined with ED reduced the risk of recurrence of stenosis (RD =–0.28, 95%?CI?[–0.47,?–0.08], P 0.01) and the required ED sessions (RD =–0.71, 95%?CI?[–1.39,?–0.04], P 0.05). TA injection therapy did not increase the risk of complications in seven studies (n=380; RD =–0.01, 95%?CI [–0.04, 0.02], P =0.53) compared with control. Conclusion: TA injection therapy after esophageal cancer surgery and combined with ED are both effective and safe in the management of stenosis, as they reduce the risk of stenosis and sequentially the required ED sessions without increasing complications.
机译:目的:根据食管癌手术后狭窄的疗效和安全性,探讨内镜手术后立即内镜注射醋酸曲安奈德(TA)并联合内镜扩张术(ED)治疗狭窄的可行性。方法:在MEDLINE,EMBASE,Cochrane图书馆,Web of Science和中国国家知识基础设施等电子数据库中进行了全面搜索,以进行可能的对照研究。使用Reviewer Manager软件完成了纳入研究的荟萃分析,并根据系统评价和荟萃分析的首选报告项目进行了报道。结果:获得了575例患者的八项随机研究和五项对照研究。在五项研究(n = 282)中,手术后注射TA降低了狭窄的风险(风险差异[RD] = –0.51,95%CI?[– 0.64,?– 0.39],P <0.01)和所需的ED疗程(RD = –3.66,95%CI?[– 5.87,?– 1.46],P <0.01)。在八项研究(n = 293)中,TA注射结合ED降低了狭窄复发的风险(RD = –0.28,95%CI?[– 0.47,?-0.08],P <0.01)和所需的ED阶段(RD = -0.71,95%CI≤[-1.39,β-0.04],P <0.05)。与对照组相比,TA注射疗法在7项研究中未增加并发症的风险(n = 380; RD = –0.01,95%?CI [–0.04,0.02],P = 0.53)。结论:食管癌手术后的TA注射疗法与ED联合治疗狭窄是既有效又安全的,因为它们降低了狭窄的风险,并在不增加并发症的情况下依次进行了必要的ED治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号